Novo Nordisk A/S
Novo Nordisk A/S (NOV.DE) Stock Competitors & Peer Comparison
See (NOV.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NOV.DE | €40.01 | +2.29% | 173.6B | 10.65 | €3.67 | +4.02% |
| VX1.DE | €365.00 | +0.70% | 92.5B | 25.26 | €14.40 | N/A |
| DUL.DE | €249.05 | -1.15% | 33.6B | 127.89 | €1.97 | N/A |
| 22UA.F | €80.85 | +0.94% | 20.1B | -15.64 | -€5.07 | N/A |
| 0QF.F | €48.83 | +18.16% | 18.5B | -6.69 | -€6.95 | N/A |
| BM8.DE | €61.96 | -1.71% | 11.8B | 88.51 | €0.70 | N/A |
| EX9.DE | €32.28 | +1.22% | 9.2B | 35.47 | €0.91 | N/A |
| BBZA.DE | €49.65 | +1.64% | 2.7B | -5.66 | -€8.60 | +5.07% |
| MOR.DE | €67.25 | -0.66% | 2.5B | -12.16 | -€5.53 | N/A |
| BIO3.DE | €32.40 | +0.62% | 1.6B | -51.75 | -€0.63 | +0.12% |
Stock Comparison
NOV.DE vs VX1.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, VX1.DE has a market cap of 92.5B. Regarding current trading prices, NOV.DE is priced at €40.01, while VX1.DE trades at €365.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas VX1.DE's P/E ratio is 25.26. In terms of profitability, NOV.DE's ROE is +0.66%, compared to VX1.DE's ROE of +0.24%. Regarding short-term risk, NOV.DE is more volatile compared to VX1.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check VX1.DE's competition here
NOV.DE vs DUL.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, DUL.DE has a market cap of 33.6B. Regarding current trading prices, NOV.DE is priced at €40.01, while DUL.DE trades at €249.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas DUL.DE's P/E ratio is 127.89. In terms of profitability, NOV.DE's ROE is +0.66%, compared to DUL.DE's ROE of +0.97%. Regarding short-term risk, NOV.DE is more volatile compared to DUL.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check DUL.DE's competition here
NOV.DE vs 22UA.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 22UA.F has a market cap of 20.1B. Regarding current trading prices, NOV.DE is priced at €40.01, while 22UA.F trades at €80.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 22UA.F's P/E ratio is -15.64. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 22UA.F's ROE of -0.06%. Regarding short-term risk, NOV.DE is more volatile compared to 22UA.F. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check 22UA.F's competition here
NOV.DE vs 0QF.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 0QF.F has a market cap of 18.5B. Regarding current trading prices, NOV.DE is priced at €40.01, while 0QF.F trades at €48.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 0QF.F's P/E ratio is -6.69. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 0QF.F's ROE of -0.37%. Regarding short-term risk, NOV.DE is less volatile compared to 0QF.F. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check 0QF.F's competition here
NOV.DE vs BM8.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, BM8.DE has a market cap of 11.8B. Regarding current trading prices, NOV.DE is priced at €40.01, while BM8.DE trades at €61.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas BM8.DE's P/E ratio is 88.51. In terms of profitability, NOV.DE's ROE is +0.66%, compared to BM8.DE's ROE of +0.09%. Regarding short-term risk, NOV.DE is more volatile compared to BM8.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check BM8.DE's competition here
NOV.DE vs EX9.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, EX9.DE has a market cap of 9.2B. Regarding current trading prices, NOV.DE is priced at €40.01, while EX9.DE trades at €32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas EX9.DE's P/E ratio is 35.47. In terms of profitability, NOV.DE's ROE is +0.66%, compared to EX9.DE's ROE of +0.22%. Regarding short-term risk, NOV.DE is more volatile compared to EX9.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check EX9.DE's competition here
NOV.DE vs BBZA.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, BBZA.DE has a market cap of 2.7B. Regarding current trading prices, NOV.DE is priced at €40.01, while BBZA.DE trades at €49.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas BBZA.DE's P/E ratio is -5.66. In terms of profitability, NOV.DE's ROE is +0.66%, compared to BBZA.DE's ROE of -0.12%. Regarding short-term risk, NOV.DE is more volatile compared to BBZA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check BBZA.DE's competition here
NOV.DE vs MOR.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, MOR.DE has a market cap of 2.5B. Regarding current trading prices, NOV.DE is priced at €40.01, while MOR.DE trades at €67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas MOR.DE's P/E ratio is -12.16. In terms of profitability, NOV.DE's ROE is +0.66%, compared to MOR.DE's ROE of -1.84%. Regarding short-term risk, NOV.DE is more volatile compared to MOR.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check MOR.DE's competition here
NOV.DE vs BIO3.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, BIO3.DE has a market cap of 1.6B. Regarding current trading prices, NOV.DE is priced at €40.01, while BIO3.DE trades at €32.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas BIO3.DE's P/E ratio is -51.75. In terms of profitability, NOV.DE's ROE is +0.66%, compared to BIO3.DE's ROE of -0.05%. Regarding short-term risk, NOV.DE is more volatile compared to BIO3.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check BIO3.DE's competition here
NOV.DE vs NVV1.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, NVV1.F has a market cap of 1.4B. Regarding current trading prices, NOV.DE is priced at €40.01, while NVV1.F trades at €8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas NVV1.F's P/E ratio is -18.06. In terms of profitability, NOV.DE's ROE is +0.66%, compared to NVV1.F's ROE of +0.90%. Regarding short-term risk, NOV.DE is less volatile compared to NVV1.F. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check NVV1.F's competition here
NOV.DE vs BIO.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, BIO.DE has a market cap of 1.3B. Regarding current trading prices, NOV.DE is priced at €40.01, while BIO.DE trades at €39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas BIO.DE's P/E ratio is -61.90. In terms of profitability, NOV.DE's ROE is +0.66%, compared to BIO.DE's ROE of -0.05%. Regarding short-term risk, NOV.DE is more volatile compared to BIO.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check BIO.DE's competition here
NOV.DE vs IMU.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, IMU.DE has a market cap of 1.1B. Regarding current trading prices, NOV.DE is priced at €40.01, while IMU.DE trades at €5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas IMU.DE's P/E ratio is -9.22. In terms of profitability, NOV.DE's ROE is +0.66%, compared to IMU.DE's ROE of -0.93%. Regarding short-term risk, NOV.DE is more volatile compared to IMU.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check IMU.DE's competition here
NOV.DE vs GBY.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, GBY.DE has a market cap of 884.7M. Regarding current trading prices, NOV.DE is priced at €40.01, while GBY.DE trades at €5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas GBY.DE's P/E ratio is -4.38. In terms of profitability, NOV.DE's ROE is +0.66%, compared to GBY.DE's ROE of -1.85%. Regarding short-term risk, NOV.DE is more volatile compared to GBY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check GBY.DE's competition here
NOV.DE vs 5CV.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 5CV.DE has a market cap of 879.5M. Regarding current trading prices, NOV.DE is priced at €40.01, while 5CV.DE trades at €3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 5CV.DE's P/E ratio is 6.85. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 5CV.DE's ROE of +0.18%. Regarding short-term risk, NOV.DE is more volatile compared to 5CV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check 5CV.DE's competition here
NOV.DE vs 5CV.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 5CV.F has a market cap of 879.5M. Regarding current trading prices, NOV.DE is priced at €40.01, while 5CV.F trades at €3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 5CV.F's P/E ratio is 6.85. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 5CV.F's ROE of +0.18%. Regarding short-term risk, NOV.DE is more volatile compared to 5CV.F. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check 5CV.F's competition here
NOV.DE vs 2EM.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 2EM.DE has a market cap of 586M. Regarding current trading prices, NOV.DE is priced at €40.01, while 2EM.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 2EM.DE's P/E ratio is 34.38. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 2EM.DE's ROE of +0.20%. Regarding short-term risk, NOV.DE is more volatile compared to 2EM.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check 2EM.DE's competition here
NOV.DE vs FYB.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, FYB.DE has a market cap of 332.3M. Regarding current trading prices, NOV.DE is priced at €40.01, while FYB.DE trades at €18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas FYB.DE's P/E ratio is -5.14. In terms of profitability, NOV.DE's ROE is +0.66%, compared to FYB.DE's ROE of -0.16%. Regarding short-term risk, NOV.DE is more volatile compared to FYB.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check FYB.DE's competition here
NOV.DE vs 2VSA.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 2VSA.F has a market cap of 285.9M. Regarding current trading prices, NOV.DE is priced at €40.01, while 2VSA.F trades at €4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 2VSA.F's P/E ratio is -1.60. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 2VSA.F's ROE of -18.50%. Regarding short-term risk, NOV.DE is less volatile compared to 2VSA.F. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check 2VSA.F's competition here
NOV.DE vs 94E.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 94E.F has a market cap of 248.4M. Regarding current trading prices, NOV.DE is priced at €40.01, while 94E.F trades at €4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 94E.F's P/E ratio is -4.11. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 94E.F's ROE of -0.84%. Regarding short-term risk, NOV.DE is more volatile compared to 94E.F. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check 94E.F's competition here
NOV.DE vs VSC.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, VSC.DE has a market cap of 150.7M. Regarding current trading prices, NOV.DE is priced at €40.01, while VSC.DE trades at €2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas VSC.DE's P/E ratio is -7.27. In terms of profitability, NOV.DE's ROE is +0.66%, compared to VSC.DE's ROE of -0.90%. Regarding short-term risk, NOV.DE is more volatile compared to VSC.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check VSC.DE's competition here
NOV.DE vs IF0.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, IF0.DE has a market cap of 129.9M. Regarding current trading prices, NOV.DE is priced at €40.01, while IF0.DE trades at €2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas IF0.DE's P/E ratio is -2.43. In terms of profitability, NOV.DE's ROE is +0.66%, compared to IF0.DE's ROE of -0.45%. Regarding short-term risk, NOV.DE is more volatile compared to IF0.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check IF0.DE's competition here
NOV.DE vs HPHA.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, HPHA.DE has a market cap of 127.7M. Regarding current trading prices, NOV.DE is priced at €40.01, while HPHA.DE trades at €2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas HPHA.DE's P/E ratio is -3.14. In terms of profitability, NOV.DE's ROE is +0.66%, compared to HPHA.DE's ROE of -54.61%. Regarding short-term risk, NOV.DE is more volatile compared to HPHA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check HPHA.DE's competition here
NOV.DE vs GBM.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, GBM.F has a market cap of 81.4M. Regarding current trading prices, NOV.DE is priced at €40.01, while GBM.F trades at €1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas GBM.F's P/E ratio is -0.77. In terms of profitability, NOV.DE's ROE is +0.66%, compared to GBM.F's ROE of -0.80%. Regarding short-term risk, NOV.DE is less volatile compared to GBM.F. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check GBM.F's competition here
NOV.DE vs 88Q.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 88Q.DE has a market cap of 81.3M. Regarding current trading prices, NOV.DE is priced at €40.01, while 88Q.DE trades at €5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 88Q.DE's P/E ratio is -4.57. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 88Q.DE's ROE of -0.75%. Regarding short-term risk, NOV.DE is more volatile compared to 88Q.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check 88Q.DE's competition here
NOV.DE vs BNN.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, BNN.DE has a market cap of 69.3M. Regarding current trading prices, NOV.DE is priced at €40.01, while BNN.DE trades at €3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas BNN.DE's P/E ratio is -6.47. In terms of profitability, NOV.DE's ROE is +0.66%, compared to BNN.DE's ROE of -3.38%. Regarding short-term risk, NOV.DE is less volatile compared to BNN.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check BNN.DE's competition here
NOV.DE vs C6O.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, C6O.DE has a market cap of 13.2M. Regarding current trading prices, NOV.DE is priced at €40.01, while C6O.DE trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas C6O.DE's P/E ratio is -0.05. In terms of profitability, NOV.DE's ROE is +0.66%, compared to C6O.DE's ROE of +1.21%. Regarding short-term risk, NOV.DE is less volatile compared to C6O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check C6O.DE's competition here
NOV.DE vs GBMB.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, GBMB.F has a market cap of 12.6M. Regarding current trading prices, NOV.DE is priced at €40.01, while GBMB.F trades at €0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas GBMB.F's P/E ratio is -0.08. In terms of profitability, NOV.DE's ROE is +0.66%, compared to GBMB.F's ROE of -0.80%. Regarding short-term risk, NOV.DE is more volatile compared to GBMB.F. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check GBMB.F's competition here
NOV.DE vs CNW.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, CNW.DE has a market cap of 6.5M. Regarding current trading prices, NOV.DE is priced at €40.01, while CNW.DE trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas CNW.DE's P/E ratio is -0.44. In terms of profitability, NOV.DE's ROE is +0.66%, compared to CNW.DE's ROE of -0.49%. Regarding short-term risk, NOV.DE is less volatile compared to CNW.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check CNW.DE's competition here
NOV.DE vs LD6.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, LD6.F has a market cap of 4.5M. Regarding current trading prices, NOV.DE is priced at €40.01, while LD6.F trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas LD6.F's P/E ratio is -1.01. In terms of profitability, NOV.DE's ROE is +0.66%, compared to LD6.F's ROE of -3.29%. Regarding short-term risk, NOV.DE is less volatile compared to LD6.F. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check LD6.F's competition here
NOV.DE vs MDG1.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, MDG1.DE has a market cap of 2M. Regarding current trading prices, NOV.DE is priced at €40.01, while MDG1.DE trades at €0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas MDG1.DE's P/E ratio is -0.11. In terms of profitability, NOV.DE's ROE is +0.66%, compared to MDG1.DE's ROE of -0.56%. Regarding short-term risk, NOV.DE is less volatile compared to MDG1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check MDG1.DE's competition here
NOV.DE vs MDG1.F Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, MDG1.F has a market cap of 451K. Regarding current trading prices, NOV.DE is priced at €40.01, while MDG1.F trades at €0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas MDG1.F's P/E ratio is -0.03. In terms of profitability, NOV.DE's ROE is +0.66%, compared to MDG1.F's ROE of -0.56%. Regarding short-term risk, NOV.DE is less volatile compared to MDG1.F. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check MDG1.F's competition here
NOV.DE vs T5O.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, T5O.DE has a market cap of 164.4K. Regarding current trading prices, NOV.DE is priced at €40.01, while T5O.DE trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas T5O.DE's P/E ratio is -0.25. In terms of profitability, NOV.DE's ROE is +0.66%, compared to T5O.DE's ROE of -1.91%. Regarding short-term risk, NOV.DE is less volatile compared to T5O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check T5O.DE's competition here
NOV.DE vs 8CC1.DU Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, 8CC1.DU has a market cap of 0. Regarding current trading prices, NOV.DE is priced at €40.01, while 8CC1.DU trades at €0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas 8CC1.DU's P/E ratio is N/A. In terms of profitability, NOV.DE's ROE is +0.66%, compared to 8CC1.DU's ROE of N/A. Regarding short-term risk, NOV.DE is less volatile compared to 8CC1.DU. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check 8CC1.DU's competition here
NOV.DE vs MGNK.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, MGNK.DE has a market cap of 0. Regarding current trading prices, NOV.DE is priced at €40.01, while MGNK.DE trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas MGNK.DE's P/E ratio is N/A. In terms of profitability, NOV.DE's ROE is +0.66%, compared to MGNK.DE's ROE of +4.09%. Regarding short-term risk, NOV.DE is less volatile compared to MGNK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check MGNK.DE's competition here
NOV.DE vs AXP.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, AXP.DE has a market cap of 0. Regarding current trading prices, NOV.DE is priced at €40.01, while AXP.DE trades at €153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas AXP.DE's P/E ratio is 59.63. In terms of profitability, NOV.DE's ROE is +0.66%, compared to AXP.DE's ROE of +0.05%. Regarding short-term risk, NOV.DE is more volatile compared to AXP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NOV.DE.Check AXP.DE's competition here
NOV.DE vs CNWK.DE Comparison May 2026
NOV.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOV.DE stands at 173.6B. In comparison, CNWK.DE has a market cap of 0. Regarding current trading prices, NOV.DE is priced at €40.01, while CNWK.DE trades at €2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOV.DE currently has a P/E ratio of 10.65, whereas CNWK.DE's P/E ratio is -5.82. In terms of profitability, NOV.DE's ROE is +0.66%, compared to CNWK.DE's ROE of -0.86%. Regarding short-term risk, NOV.DE is less volatile compared to CNWK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for NOV.DE.Check CNWK.DE's competition here